RU2020121363A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2020121363A3 RU2020121363A3 RU2020121363A RU2020121363A RU2020121363A3 RU 2020121363 A3 RU2020121363 A3 RU 2020121363A3 RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A RU2020121363 A RU 2020121363A RU 2020121363 A3 RU2020121363 A3 RU 2020121363A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 | |
CN202180044905.7A CN115803026A (en) | 2020-06-26 | 2021-06-18 | Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity |
BR112022026356A BR112022026356A2 (en) | 2020-06-26 | 2021-06-18 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES ASSOCIATED WITH ABERRANT INTERLEUKIN-6 ACTIVITY |
PCT/RU2021/050170 WO2021262040A1 (en) | 2020-06-26 | 2021-06-18 | Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity |
MA58653A MA58653B1 (en) | 2020-06-26 | 2021-06-18 | USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY |
CL2022003725A CL2022003725A1 (en) | 2020-06-26 | 2022-12-22 | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity. |
CONC2023/0000604A CO2023000604A2 (en) | 2020-06-26 | 2023-01-19 | Use of a glutarimide derivative for the treatment of diseases associated with aberrant interleukin-6 activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (en) | 2020-06-26 | Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022116762A Division RU2022116762A (en) | 2022-06-22 | USE OF GLUTARIMIDE DERIVATIVE FOR THE THERAPY OF DISEASES ASSOCIATED WITH ABERRANT ACTIVITY OF INTERLEUKIN-6 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2020121363A RU2020121363A (en) | 2021-12-27 |
RU2020121363A3 true RU2020121363A3 (en) | 2021-12-27 |
RU2774928C2 RU2774928C2 (en) | 2022-06-27 |
Family
ID=
Also Published As
Publication number | Publication date |
---|---|
MA58653A1 (en) | 2023-07-31 |
BR112022026356A2 (en) | 2023-01-17 |
CL2022003725A1 (en) | 2023-05-19 |
RU2020121363A (en) | 2021-12-27 |
MA58653B1 (en) | 2024-02-29 |
WO2021262040A1 (en) | 2021-12-30 |
CO2023000604A2 (en) | 2023-01-26 |
CN115803026A (en) | 2023-03-14 |